Phaseline

Targets › DYRK2

DYRK2 (Dual specificity tyrosine-phosphorylation-regulated kinase 2): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Dec 2026.

Serine/threonine-protein kinase involved in the regulation of the mitotic cell cycle, cell proliferation, apoptosis, organization of the cytoskeleton and neurite outgrowth. Phosphorylates CRMP2/DPYSL2, CRMP4/DPYSL3, DCX, EIF2B5, EIF4EBP1, GLI2, GLI3, GYS1, JUN, MDM2, MYC, NFATC1, p53/TP53, TAU/MAPT and KATNA1. (UniProt, Q92630)

Open in Phaseline: the race on DYRK2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Tasly PharmaceuticalsTSL2109
CDK4/6-DYRK2 dual-target inhibitor
CDK4, CDK6, DYRK2Phase 1Metastatic Castration-Resistant Prostate Cancer PatientsDec 2026

Conditions

Metastatic Castration-Resistant Prostate Cancer Patients (1)

Modalities

small molecule (1)

Companies

Tasly Pharmaceuticals (1)

Related targets

CDK4 (1) CDK6 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.